Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. - Wikidata - awgldk - TriplyDB

Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

http://www.wikidata.org/entity/Q48567214

about

Therapeutic strategies for inhibiting invasion in glioblastoma.Experimental approaches for the treatment of malignant gliomas.Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells.Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.Molecularly targeted therapies for malignant gliomas: advances and challenges.Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma.Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatment.Optimizing antiepileptic drug treatment in tumoral epilepsy.Current and emerging therapeutic strategies for preventing inflammation and aggrecanase-mediated cartilage destruction in arthritis.Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.Investigating the Cellular Specificity in Tumors of a Surface-Converting Nanoparticle by Multimodal Imaging Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.Considerations on inhibition approaches for proinflammatory functions of ADAM proteases.The role of matrix metalloproteinases in the pathophysiology and progression of human nervous system malignancies: a chance for the development of targeted therapeutic approaches?

P2860

Q33426563-EB7D70B1-B430-4373-ACF6-8CAD783B2D4A Q34127138-D3089792-97B3-4DD2-8A81-4AEED0C9309A Q35403440-DF967364-165E-4ED9-A79F-1F247B1075F1 Q35891348-2565AFBB-8378-4263-96E6-7A1F7247E518 Q36288254-DA58F0A7-0C70-477A-A4AA-F8334454E3DC Q36668246-FF89CE94-2CEE-474E-AC48-DFEFF4916CEB Q36817109-5E34AB09-589C-4EB6-9BDD-E9B000630EEF Q37236243-CBB5D121-3B50-4A51-B2B8-83E45AEF2017 Q37393984-6C268D52-B052-41F4-99BE-D63588C1B5F4 Q38105151-672B8608-F881-4472-BB7A-C3A92549E241 Q38170433-09E4A159-417D-4111-9FF0-E1A8C889A04A Q38326581-B6B46D71-B38C-4B3E-ABDD-C15B86A726F2 Q38870841-4A960A13-D64A-4F44-B2CD-3C70D7D8F806 Q38895968-6FEA8924-A512-4A87-9616-7856D882558C Q39196377-3070C9FE-F8D8-421B-8083-21A4FAD3597C Q39798606-21B56652-E958-49B5-B4E6-00538E5B6816 Q47965779-00D4873E-96B0-4BA2-AD78-2D0E27AE7B31 Q50495797-EEF5660B-611C-4BA9-99F3-1C04FB31B792 Q57693482-2BD5450B-29FB-4B66-A52F-B8490C78EFD7

P2860

Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

http://www.wikidata.org/entity/Q48567214

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Phase II trial of temozolomide ...... ity and anticonvulsant status.

@en

Phase II trial of temozolomide ...... ity and anticonvulsant status.

@nl

type

label

Phase II trial of temozolomide ...... ity and anticonvulsant status.

@en

Phase II trial of temozolomide ...... ity and anticonvulsant status.

@nl

prefLabel

Phase II trial of temozolomide ...... ity and anticonvulsant status.

@en

Phase II trial of temozolomide ...... ity and anticonvulsant status.

@nl

P1433

Q48567214-F4F640BB-6CDD-49C1-BC1A-33D76509F532

P1476

Q48567214-BECA2206-B0F7-42AB-B80D-FA36C39A5C2C

P2093

Q48567214-1CECA235-B4F3-413F-B0C4-23A9DB7ADF4D

Q48567214-2772307D-701F-4518-B67D-21EB43499D46

Q48567214-59E29546-58DC-46E8-8676-047E68F4F937

Q48567214-6148FE1B-651D-4813-89B0-B55CEAD90CE1

Q48567214-6722CE2E-FCE4-4571-B907-DD712BE9816D

Q48567214-6BDEEE65-ABCD-4082-9830-D51214786C2A

Q48567214-8309282E-50BA-4F71-8817-7A3B606E8FAC

Q48567214-9F3A78FD-6B85-4494-8695-01B733EB6B62

Q48567214-AC5DD5E1-2090-4C27-A383-F7243F51F382

Q48567214-EF92233E-CD62-4EFD-9F79-19A9E276C816

P2860

Q48567214-A1AB6955-57F6-41B4-9635-151A8765FDE5

P2888

Q48567214-18F7BD90-247D-49A6-8FE9-8EAB023BEFF6

P304

Q48567214-C1ED9BF1-019F-4662-890F-75C9E0067028

P31

Q48567214-C4B28308-CC37-48A3-AC22-E44D84EBD5A0

P356

Q48567214-2925745A-FD40-4CD7-8B96-553ABD585551

P433

Q48567214-DDF94500-4FBE-4B5A-9454-C9DE7D890A47

P478

Q48567214-ADD243AC-7F0D-45BD-839E-BDB8F3616D06

P577

Q48567214-B993DF1A-14DC-41B5-BB75-F25E957ABE38

P698

Q48567214-7023F302-3D6F-4853-8BCF-BEC39660CEE9

P921

Q48567214-A5FBDF41-69CE-4A15-82F3-D72B0DD45D36

P356

S11060-006-9160-Y

P1433

Journal of Neuro-Oncology

P1476

Phase II trial of temozolomide ...... ity and anticonvulsant status.

@en

P2093

Charles A Conrad

http://www.w3.org/2001/XMLSchema#string

Kenneth D Aldape

http://www.w3.org/2001/XMLSchema#string

Kenneth R Hess

http://www.w3.org/2001/XMLSchema#string

Kurt Jaeckle

http://www.w3.org/2001/XMLSchema#string

Mark R Gilbert

http://www.w3.org/2001/XMLSchema#string

Morris D Groves

http://www.w3.org/2001/XMLSchema#string

Victor A Levin

http://www.w3.org/2001/XMLSchema#string

Vinay K Puduvalli

http://www.w3.org/2001/XMLSchema#string

Vivien Liu

http://www.w3.org/2001/XMLSchema#string

W K Alfred Yung

http://www.w3.org/2001/XMLSchema#string

P2860

Matrix metalloproteinases in human gliomas: activation of matrix metalloproteinase-2 (MMP-2) may be correlated with membrane-type-1 matrix metalloproteinase (MT1-MMP) expression.

P2888

s11060-006-9160-y

P304

83-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-006-9160-Y

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16639492

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial